Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Treasury Shares: 2022-2025

Historic Treasury Shares for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $1.0 million.

  • Axsome Therapeutics' Treasury Shares rose 11.98% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 11.98%. This contributed to the annual value of $906,944 for FY2024, which is 12.78% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Treasury Shares stood at $1.0 million, which was down 3.41% from $1.0 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Treasury Shares high stood at $1.0 million for Q2 2025, and its period low was $667,366 during Q1 2022.
  • For the 3-year period, Axsome Therapeutics' Treasury Shares averaged around $893,725, with its median value being $899,277 (2024).
  • Data for Axsome Therapeutics' Treasury Shares shows a peak YoY grew of 17.95% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Treasury Shares (Quarterly) stood at $686,375 in 2022, then climbed by 17.16% to $804,150 in 2023, then climbed by 12.78% to $906,944 in 2024, then grew by 11.98% to $1.0 million in 2025.
  • Its Treasury Shares stands at $1.0 million for Q3 2025, versus $1.0 million for Q2 2025 and $993,202 for Q1 2025.